BIO VITOS PHARMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.18 SEK | +0.84% |
|
-4.51% | -24.37% |
| 02-14 | Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-14 | Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 4.74M 438K 599K | Sales 2023 | 3M 277K 378K | Capitalization | 8.18M 755K 1.03M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.29M -1.77M | Net income 2023 | -12M -1.11M -1.52M | EV / Sales 2022 | 0.7 x |
| Net cash position 2022 | 3.19M 294K 402K | Net cash position 2023 | 3.07M 284K 388K | EV / Sales 2023 | 1.7 x |
| P/E ratio 2022 |
-0.33
x | P/E ratio 2023 |
-1.04
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 7.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.84% | ||
| 1 week | -4.51% | ||
| 1 month | -19.28% | ||
| 3 months | +0.56% | ||
| 6 months | -39.80% | ||
| Current year | -24.37% |
1 week
0.18
0.19
1 month
0.180.25
Current year
0.140.28
1 year
0.080.49
3 years
0.083.90
5 years
0.087.64
10 years
0.0817.60
| Managers | Title | Age | Since |
|---|---|---|---|
Joen Averstad
CEO | Chief Executive Officer | 40 | 11-12-31 |
Robert Thorén
DFI | Director of Finance/CFO | 47 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 50 | 09-12-31 | |
| Founder | 52 | 09-12-31 | |
| Director/Board Member | 65 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 0.18 | +0.84% | 25 002 |
| 24-05-03 | 0.1785 | +0.85% | 9,403 |
| 24-05-02 | 0.177 | -1.67% | 23,799 |
| 24-04-30 | 0.18 | -4.51% | 30,055 |
| 24-04-29 | 0.1885 | +1.89% | 105,081 |
Delayed Quote Nasdaq Stockholm, May 06, 2024 at 03:34 am
More quotes
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.37% | 4.86M | |
| -2.14% | 12.56B | |
| -9.59% | 7.68B | |
| -0.75% | 5.29B | |
| +21.82% | 5.24B | |
| +0.02% | 4.57B | |
| -50.89% | 3.29B | |
| +6.42% | 2.6B | |
| -9.55% | 2.2B | |
| -8.29% | 1.79B |
- Stock Market
- Equities
- BIOVIT Stock